Management of Viral Hepatitis in Solid Organ Transplant Recipients

Buganza-Torio, Elizabeth; Doucette, Karen

doi:10.1016/j.idc.2018.04.010

Cited by 9 publications

(1 citation statement)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In cases of rapidly progressive infection with pan-resistant bacterial strains before or after transplant, targeted combination antibiotic therapy is indicated for eradication (57,58). Bacteriophage therapy is a novel strategy for treatment of multi-drug-resistant bacterial infections; its use has been reported in 3 (61). Overall, patients with the above-mentioned infections are more commonly being considered suitable transplant candidates, despite existing guidelines, when these patients are evaluated at transplant centers with significant experience in managing these infections in the transplant setting.…”

Section: Colonization and Infectionmentioning

confidence: 99%

Current trends in candidate selection, contraindications, and indications for lung transplantation

Arjuna¹,

Olson²,

Walia³

2021

J Thorac Dis

View full text Add to dashboard Cite

Lung transplant has been established as the treatment of choice for patients with various forms of end-stage lung disease, in whom non-transplant therapeutic options have failed. Many advances in the realms of basic science, clinical research, surgical technique, and perioperative management have emerged over the past few decades; these innovations have contributed to substantial improvements in survival and quality of life for transplant recipients. However, the field of lung transplantation faces appreciable challenges, including expanding the lung donor pool and ameliorating posttransplant complications, such as primary graft dysfunction, cellular-and antibodymediated rejection, chronic lung allograft dysfunction, and infection (1). One of the most important questions

show abstract

Section: Colonization and Infectionmentioning

confidence: 99%

Current trends in candidate selection, contraindications, and indications for lung transplantation

Arjuna¹,

Olson²,

Walia³

2021

J Thorac Dis

View full text Add to dashboard Cite

show abstract

Infections in Heart Transplantation

Tsai,

Minamoto,

Puius

2023

Textbook of Transplantation and Mechanical Support for End‐Stage Heart and Lung Disease

View full text Add to dashboard Cite

Acute cellular rejection in hepatitis C recipients following liver transplantation in the era of direct‐acting antivirals: chronological analysis of the United Network for Organ Sharing database

Tanaka

Voigt

2019

J Hepato Biliary Pancreat

View full text Add to dashboard Cite

IntroductionInterferon (IFN) treatment for liver transplant (LT) recipients with hepatitis C virus (HCV) increases acute cellular rejection (ACR) and worsens graft and patient survival. It is unknown if direct‐acting antivirals (DAAs) affect rejection rates or post‐transplant survival.MethodThe United Network for Organ Sharing STAR files of December 2017 (n = 25,916) were analyzed.ResultsCompared with non‐HCV‐LT, HCV‐LT survival was worse in the IFN‐era (2007–2008) and IFN+DAA‐era (2011), but not in the DAA‐era (2014–2015). ACR6m rate has been less frequent in newer eras and was lower in HCV‐LT than in non‐HCV‐LT in both the DAA‐era (6.9% vs. 9.3%, P < 0.001) and in the IFN+DAA‐era (8.8% vs. 11.8%, P = 0.001), but not in the IFN‐era (10.8% vs. 11.0%, P = 0.39). HCV‐LT recipients who had ACR6m had worse 2‐year survival than those without ACR6m, in the IFN‐era (80.0% vs. 88.4%, P < 0.0001) and in the IFN+DAA‐era (81.4% vs. 89.2%, P < 0.01) but not in the DAA‐era (90.4% vs. 93.2%, P = 0.085). Cox proportional hazard model identified ACR6m as independent risk factor for mortality in HCV‐LT in the IFN‐era (HR = 1.88, P ≤ 0.001) and in the IFN+DAA‐era (HR = 1.84, P = 0.005), but not in the DAA‐era (P = n.s.).ConclusionsTwo‐year survival of HCV‐LT recipients were significantly better in the DAA‐era; these were associated with reduced rate and impact of ACR6m.

show abstract

Management of Viral Hepatitis in Solid Organ Transplant Recipients

Cited by 9 publications

References 85 publications

Current trends in candidate selection, contraindications, and indications for lung transplantation

Current trends in candidate selection, contraindications, and indications for lung transplantation

Infections in Heart Transplantation

Acute cellular rejection in hepatitis C recipients following liver transplantation in the era of direct‐acting antivirals: chronological analysis of the United Network for Organ Sharing database

Contact Info

Product

Resources

About